Malin G. Pedersen

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Journal: Journal for immunotherapy of cancer
Published: February 07, 2026

Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma.

Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma.

Journal: Cancer discovery
Published: December 18, 2025

Expression of Concern: Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Expression of Concern: Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Journal: Cancer discovery
Published: December 18, 2025

Periodic radio and X-ray emission from an accreting white dwarf binary.

Periodic radio and X-ray emission from an accreting white dwarf binary.

Journal: Nature astronomy
Published: November 11, 2025

Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Journal: Cancer research communications
Published: October 02, 2025

Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.

Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.

Journal: Journal for immunotherapy of cancer
Published: August 27, 2025

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Journal: Nature communications
Published: July 15, 2025

ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin.

ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin.

Journal: Cell reports
Published: June 12, 2025

Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion.

Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion.

Journal: Nature metabolism
Published: September 03, 2024

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.

Journal: Journal for immunotherapy of cancer
Published: July 13, 2024

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Journal: Nature communications
Published: March 18, 2024

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Journal: Nature communications
Published: March 18, 2024
Showing 1-12 of 41

Last Updated: 09/26/2026